Most, if not all, institutional investors are barred from buying any securities that are not held on either national exchanges, or companies that do not have to follow GAAP and SOX. With smaller funds, it depends on how their fund is structured, and with mutual funds, there is 0% chance of them buying VirTra currently.
An uplist could lead to institutional investors purchasing VirTra for an Emerging Technologies or Defense Sector Mutual Fund/ETF.